These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 35681659)

  • 1. Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.
    Cozzi S; Alì E; Bardoscia L; Najafi M; Botti A; Blandino G; Giaccherini L; Ruggieri MP; Augugliaro M; Iori F; Sardaro A; Iotti C; Ciammella P
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Horne ZD; Richman AH; Dohopolski MJ; Clump DA; Burton SA; Heron DE
    Lung Cancer; 2018 Jan; 115():1-4. PubMed ID: 29290248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.
    Kowalchuk RO; Waters MR; Richardson M; Spencer K; Larner JM; Kersh CR
    Thorac Cancer; 2020 Jul; 11(7):2005-2013. PubMed ID: 32469465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results.
    Manabe Y; Shibamoto Y; Baba F; Yanagi T; Iwata H; Miyakawa A; Murai T; Okuda K
    Jpn J Radiol; 2018 Dec; 36(12):719-725. PubMed ID: 30218253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer.
    Manabe Y; Shibamoto Y; Baba F; Murata R; Yanagi T; Hashizume C; Iwata H; Kosaki K; Miyakawa A; Murai T; Yano M
    Pract Radiat Oncol; 2012; 2(4):e137-e143. PubMed ID: 24674177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
    Nicosia L; Franzese C; Mazzola R; Franceschini D; Rigo M; D'agostino G; Corradini S; Alongi F; Scorsetti M
    Strahlenther Onkol; 2020 Mar; 196(3):213-221. PubMed ID: 31559480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
    Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
    Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.
    Schröder C; Opitz I; Guckenberger M; Stahel R; Weder W; Förster R; Andratschke N; Lauk O
    Front Oncol; 2019; 9():961. PubMed ID: 31616640
    [No Abstract]   [Full Text] [Related]  

  • 13. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
    Yeung R; Hamm J; Liu M; Schellenberg D
    Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
    Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
    Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
    Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
    Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of stereotactic body radiotherapy - is volumetric modulated arc therapy the answer?
    Sapkaroski D; Osborne C; Knight KA
    J Med Radiat Sci; 2015 Jun; 62(2):142-51. PubMed ID: 26229679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
    Levy A; Khalifa J; Martin E; Botticella A; Quevrin C; Lavaud P; Aldea M; Besse B; Planchard D; Barlesi F; Deutsch E; Massabeau C; Doyen J; Le Péchoux C
    Clin Transl Radiat Oncol; 2023 Jul; 41():100637. PubMed ID: 37206411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.